Literature DB >> 20488691

Impacts of multileaf collimators leaf width on intensity-modulated radiotherapy planning for nasopharyngeal carcinoma: analysis of two commercial elekta devices.

Shichao Wang1, Youling Gong, Qingfeng Xu, Sen Bai, You Lu, Qingfeng Jiang, Nianyong Chen.   

Abstract

We compared the impacts of multileaf collimator (MLC) widths (standard MLC width of 10 mm [SMLC] and micro-MLC width of 4 mm [MMLC]) on intensity-modulated radiotherapy (IMRT) planning for nasopharyngeal carcinoma (NPC). Ten patients with NPC were recruited in this study. In each patient's case, plans were generated with the same machine setup parameter and optimizing methods in a treatment planning system according to 2 commercial Elekta MLC devices. All of the parameters were collected from dose-volume histograms of paired plans and evaluated. The average conformity index (CI) and homogeneous index (HI) for the planning gross target volume in IMRT plans with MMLC were 0.790 ± 0.036 and 1.062 ± 0.011, respectively. Data in plans with SMLC were 0.754 ± 0.038 and 1.070 ± 0.010, respectively. The differences were statistically significant (p < 0.05). Compared with CI and HI for planning target volume in paired plans, data with MMLC obviously were better than those with SMLC (CI: 0.858 ± 0.026 vs. 0.850 ± 0.021, p < 0.05; and HI: 1.185 ± 0.011 vs. 1.195 ± 0.011, p < 0.05). However, there was no statistical significance between evaluated parameters (Dmean, Dmax, D₅, gEUD, or NTCP) for organs at risk (OARs) in the 2 paired IMRT plans. According to these two kinds of Elekta MLC devices, IMRT plans with the MMLC have significant advantages in dose coverage for the targets, with more efficiency in treatment for NPC but fail to improve dose sparing of the OARs.
Copyright © 2011 American Association of Medical Dosimetrists. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20488691     DOI: 10.1016/j.meddos.2010.02.007

Source DB:  PubMed          Journal:  Med Dosim        ISSN: 1873-4022            Impact factor:   1.482


  6 in total

1.  Clinical effect of multileaf collimator width on the incidence of late rectal bleeding after high-dose intensity-modulated radiotherapy for localized prostate carcinoma.

Authors:  Haruo Inokuchi; Takashi Mizowaki; Yoshiki Norihisa; Kenji Takayama; Itaru Ikeda; Kiyonao Nakamura; Mitsuhiro Nakamura; Masahiro Hiraoka
Journal:  Int J Clin Oncol       Date:  2015-07-12       Impact factor: 3.402

2.  Effect of the simulated half leaf width of a multileaf collimator on volumetric modulated arc therapy plan quality in hippocampal avoidance whole-brain radiotherapy.

Authors:  Ming-Hsien Li; Li-Jhen Chen; Chih-Chieh Chang; Jo-Ting Tsai; Jang-Chun Lin
Journal:  J Appl Clin Med Phys       Date:  2022-03-03       Impact factor: 2.243

3.  Impact of MLC leaf width on volumetric-modulated arc therapy planning for head and neck cancers.

Authors:  Caroline Lafond; Enrique Chajon; Anne Devillers; Guillaume Louvel; Sandra Toublanc; Mickael Olivier; Antoine Simon; Renaud De Crevoisier; Jean-Pierre Manens
Journal:  J Appl Clin Med Phys       Date:  2013-11-08       Impact factor: 2.102

4.  Dosimetric impact of multileaf collimator leaf width according to sophisticated grade of technique in the IMRT and VMAT planning for pituitary adenoma lesion.

Authors:  Soo-Min Chae; Ki Woong Lee; Seok Hyun Son
Journal:  Oncotarget       Date:  2016-11-22

5.  Impact of MLC properties and IMRT technique in meningioma and head-and-neck treatments.

Authors:  Steffi Kantz; Matthias Söhn; Almut Troeller; Michael Reiner; Helmut Weingandt; Markus Alber; Claus Belka; Ute Ganswindt
Journal:  Radiat Oncol       Date:  2015-09-02       Impact factor: 3.481

6.  Volumetric modulated arc therapy versus step-and-shoot intensity modulated radiation therapy in the treatment of large nerve perineural spread to the skull base: a comparative dosimetric planning study.

Authors:  Peter Gorayski; Rhys Fitzgerald; Tamara Barry; Elizabeth Burmeister; Matthew Foote
Journal:  J Med Radiat Sci       Date:  2014-04-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.